Skip to content

Clinical Study on Plasma Characteristic Methylation Markers for Auxiliary Diagnosis and Prognostic Monitoring of Esophageal Diseases

Clinical Study on Plasma Characteristic Methylation Markers for Auxiliary Diagnosis and Prognostic Monitoring of Esophageal Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124688
Enrollment
Unknown
Registered
2026-05-15
Start date
2026-05-25
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Interventions

Healthy Control group:None

Sponsors

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Age: 20-60 years old; 2.Esophageal Cancer Patients. Patients who are first diagnosed with esophageal cancer in our hospital (either by pathological examination or imaging studies) and subsequently receive treatment at our hospital. 3.Patients with Benign Esophageal Diseases;

Exclusion criteria

Exclusion criteria: 1.Patients Who Have Received Other Treatments at External Hospitals; 2.Patients with nodules in the benign disease group who developed esophageal cancer during the study period; 3.Patients with a previous history of tumors;

Design outcomes

Primary

MeasureTime frame
Plasma Methylation Marker TFPI2;

Secondary

MeasureTime frame
Plasma Methylation Marker DMRTA2;

Countries

China

Contacts

Public ContactJiexin Zhang; Jian Xu

The First Affiliated Hospital with Nanjing Medical University

jiexinzhang@njmu.edu.cn+86 25 68303458

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026